Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 13, 2011, Pages 2553-2557

  Iida, Katsuyuki ^a  

^a MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

Advanced metastatic prostate cancer; Combined androgen blockade (CAB); Monotherapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; NILUTAMIDE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER SURVIVAL; DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; MONOTHERAPY; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857334142     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on Serum Phosphatases in Metastatic Carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
2. Labrie F, Dupont A, Belanger A, et al: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5(4): 267-275, 1982. (Pubitemid 13217099)
3. PCTCG: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355(9214): 1491-1498, 2000.
4. Akaza H, Hinotsu S, Usami M, et al: Combined androgen blockade with bicalutamide for advanced prostate cancer long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115(15): 3437-3445, 2009.
5. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321(7): 419-424, 1989. (Pubitemid 19211484)
6. Denis LJ, Keuppens F, Smith PH, et al: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 33(2): 144-151, 1998.
7. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339(15): 1036-1042, 1998. (Pubitemid 28457865)
8. Boccardo F, Pace M, Rubagotti A, et al: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 29A(8): 1088-1093, 1993. (Pubitemid 23156628)
9. Schellhammer PF, Sharifi R, Block NL, et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 50(3): 330-336, 1997. (Pubitemid 27428107)
10. Klotz L, Schellhammer P and Carroll K: A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 93(9): 1177-1182, 2004. (Pubitemid 38823930)
11. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancen 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25(12): 1596-1605, 2007. (Pubitemid 46733088)
12. Usami M, Akaza H, Arai Y, et al: Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancen findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 10(2): 194-201, 2007. (Pubitemid 46881672)
13. Arai Y, Akaza H, Deguchi T, et al: Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol 134(12): 1385-1396, 2008.
14. Nishimura S, Arai Y, Usami M, et al: Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer. Gan To Kagaku Ryoho 34(4): 589-595, 2007.
15. Scher HI, Beer TM, Higano CS, et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724): 1437-1446, 2010.